Loss of Survivin in Intestinal Epithelial Progenitor Cells Leads to Mitotic Catastrophe and Breakdown of Gut Immune Homeostasis

Cell Reports

Volumn 14, Issue 5, 2016, Pages 1062-1073

  Martini, Eva ^a   Wittkopf, Nadine ^a   Günther, Claudia ^a   Leppkes, Moritz ^a   Okada, Hitoshi ^b   Watson, Alastair J ^c   Podstawa, Eva ^a   Backert, Ingo ^a   Amann, Kerstin ^a   Neurath, Markus F ^a   Becker, Christoph ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX; PROTEIN P53; SURVIVIN; BIRC5 PROTEIN, HUMAN; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; INTESTINAL STEM CELL; MALE; MOUSE; MUCOSA INFLAMMATION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STEM CELL NICHE; ANIMAL; CELL DEATH; CELL DIVISION; CELL SURVIVAL; DEFICIENCY; GENE DELETION; HOMEOSTASIS; HUMAN; IMMUNOLOGY; INTESTINE; METABOLISM; MITOSIS; PATHOLOGY; STEM CELL; ULTRASTRUCTURE;

ANIMALS; CELL DEATH; CELL DIVISION; CELL SURVIVAL; EPITHELIAL CELLS; GENE DELETION; HOMEOSTASIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTESTINES; MICE; MITOSIS; REPRESSOR PROTEINS; STEM CELL NICHE; STEM CELLS;

EID: 84957990646     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.01.010     Document Type: Article

References (38)

1. Altieri D.C. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol. Cancer Ther. 2006, 5:478-482.
2. Barker N., van Es J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., Haegebarth A., Korving J., Begthel H., Peters P.J., Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
3. Barker N., Bartfeld S., Clevers H. Tissue-resident adult stem cell populations of rapidly self-renewing organs. Cell Stem Cell 2010, 7:656-670.
4. Barker N., van Oudenaarden A., Clevers H. Identifying the stem cell of the intestinal crypt: strategies and pitfalls. Cell Stem Cell 2012, 11:452-460.
5. Beisner D.R., Ch'en I.L., Kolla R.V., Hoffmann A., Hedrick S.M. Cutting edge: innate immunity conferred by B cells is regulated by caspase-8. J. Immunol. 2005, 175:3469-3473.
6. Boman B., Kopelovich L., Siracusa L.D., Zhang T., Henderson K., Cofer Z., Buchberg A.M., Fields J.Z., Otevrel T. A Tcf4-GFP reporter mouse model for monitoring effects of Apc mutations during intestinal tumorigenesis. Mol. Carcinog. 2009, 48:821-831.
7. Chu X.-Y., Chen L.-B., Wang J.-H., Su Q.-S., Yang J.-R., Lin Y., Xue L.-J., Liu X.B., Mo X.B. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J. Surg. Oncol. 2012, 105:520-528.
8. Conway E.M., Pollefeyt S., Steiner-Mosonyi M., Luo W., Devriese A., Lupu F., Bono F., Leducq N., Dol F., Schaeffer P., et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002, 123:619-631.
9. el Marjou F., Janssen K.-P., Chang B.H.-J., Li M., Hindie V., Chan L., Louvard D., Chambon P., Metzger D., Robine S. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004, 39:186-193.
10. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5:1087-1098.
11. Günther C., Martini E., Wittkopf N., Amann K., Weigmann B., Neumann H., Waldner M.J., Hedrick S.M., Tenzer S., Neurath M.F., Becker C. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 2011, 477:335-339.
12. Hagemann S., Wohlschlaeger J., Bertram S., Levkau B., Musacchio A., Conway E.M., Moellmann D., et al. Loss of Survivin influences liver regeneration and is associated with impaired Aurora B function. Cell Death Differ. 2013, 20:834-844.
13. Huang Y.-J., Qi W.-X., He A.-N., Sun Y.-J., Shen Z., Yao Y. The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis. Jpn. J. Clin. Oncol. 2013, 43:988-995.
14. Jiang Y., de Bruin A., Caldas H., Fangusaro J., Hayes J., Conway E.M., Robinson M.L., Altura R.A. Essential role for survivin in early brain development. J. Neurosci. 2005, 25:6962-6970.
15. Kelly R.J., Thomas A., Rajan A., Chun G., Lopez-Chavez A., Szabo E., Spencer S., et al. A phase I/II study of sepantronium bromide (YM155, Survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013, 24:2601-2606.
16. Levkau B., Schäfers M., Wohlschlaeger J., von Wnuck Lipinski K., Keul P., Hermann S., Kawaguchi N., Kirchhof P., Fabritz L., Stypmann J., et al. Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation 2008, 117:1583-1593.
17. Li F., Brattain M.G. Role of the Survivin gene in pathophysiology. Am. J. Pathol. 2006, 169:1-11.
18. Miura K., Fujibuchi W., Ishida K., Naitoh T., Ogawa H., Ando T., Yazaki N., Watanabe K., Haneda S., Shibata C., Sasaki I. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg. Today 2011, 41:175-182.
19. Mobahat M., Narendran A., Riabowol K. Survivin as a preferential target for cancer therapy. Int. J. Mol. Sci. 2014, 15:2494-2516.
20. Nenci A., Becker C., Wullaert A., Gareus R., van Loo G., Danese S., Huth M., Nikolaev A., Neufert C., Madison B., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007, 446:557-561.
21. Newton K., Sun X., Dixit V.M. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell. Biol. 2004, 24:1464-1469.
22. Okada H., Bakal C., Shahinian A., Elia A., Wakeham A., Suh W.-K., Duncan G.S., Ciofani M., Rottapel R., Zúñiga-Pflücker J.C., Mak T.W. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J. Exp. Med. 2004, 199:399-410.
23. Sancho E., Batlle E., Clevers H. Live and let die in the intestinal epithelium. Curr. Opin. Cell Biol. 2003, 15:763-770.
24. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
25. Satoh T., Okamoto I., Miyazaki M., Morinaga R., Tsuya A., Hasegawa Y., Terashima M., Ueda S., Fukuoka M., Ariyoshi Y., et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:3872-3880.
26. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., Chung C.W., Jung Y.K., Oh B.H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
27. Talbot D.C., Ranson M., Davies J., Lahn M., Callies S., André V., Kadam S., Burgess M., Slapak C., Olsen A.L., et al. Tumor Survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res. 2010, 16:6150-6158.
28. Tanaka T., Kitamura H., Inoue R., Nishida S., Takahashi-Takaya A., Kawami S., Torigoe T., Hirohashi Y., Tsukamoto T., Sato N., Masumori N. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials. Clin. Dev. Immunol. 2013, 2013:262967.
29. Tian H., Biehs B., Warming S., Leong K.G., Rangell L., Klein O.D., de Sauvage F.J. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011, 478:255-259.
30. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., Patnaik A., Papadopoulos K., Takimoto C., Bartels P., et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 2008, 26:5198-5203.
31. Tolcher A.W., Quinn D.I., Ferrari A., Ahmann F., Giaccone G., Drake T., Keating A., de Bono J.S. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann. Oncol. 2012, 23:968-973.
32. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., Choo K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 2000, 10:1319-1328.
33. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
34. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 2000, 7:602-608.
35. Vitale I., Galluzzi L., Castedo M., Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 2011, 12:385-392.
36. Wu X., Wang L., Schroer S., Choi D., Chen P., Okada H., Woo M. Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice. Diabetologia 2009, 52:2130-2141.
37. Yin X., Farin H.F., van Es J.H., Clevers H., Langer R., Karp J.M. Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat. Methods 2014, 11:106-112.
38. Zwerts F., Lupu F., De Vriese A., Pollefeyt S., Moons L., Altura R.A., Jiang Y., Maxwell P.H., Hill P., Oh H., et al. Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood 2007, 109:4742-4752.